Literature DB >> 10069535

Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity.

R E Devoll1, W Li, K V Woods, G J Pinero, W T Butler, M C Farach-Carson, R P Happonen.   

Abstract

The objectives of this study were to assess the immunolocalization of human osteopontin (OPN) in oral lesions and to identify human cell lines of oral squamous cell carcinoma (OSCC) origin that express OPN mRNA. OPN was localized using immunohistochemistry in the following oral specimens: normal epithelium (n=6), epithelial hyperplasia (n=4), epithelial dysplasia (n=28), carcinoma in situ (n=11) and squamous cell carcinoma (n=43). Cell lines UMSCC-1, MDA TU 138, MDA 686LN, SCC4, SCC9, SCC25, CAL 27 and MDA 1483 were characterized for OPN mRNA expression using Northern blotting. OPN was not detected in normal oral epithelium. Intracellular and intercellular immunoreactivity was seen in 75% of hyperplasias, 57% of dysplasias, 54% of carcinoma in situ and 67% of squamous cell carcinomas. UMSCC-1 expressed high levels of OPN mRNA. We conclude that OPN protein is detectable in premalignant and malignant lesions arising from oral epithelium. UMSCC-1 may be a useful cell line in which to conduct in vitro studies designed to clarify the role of OPN in OSCC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10069535     DOI: 10.1111/j.1600-0714.1999.tb02004.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  13 in total

1.  Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Authors:  Xianmin Luo; Megan K Ruhland; Ermira Pazolli; Anne C Lind; Sheila A Stewart
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

2.  Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma.

Authors:  Kalu U E Ogbureke; Rafik A Abdelsayed; Harvey Kushner; Li Li; Larry W Fisher
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

3.  Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells.

Authors:  Yu-Hua Hsieh; M Margaret Juliana; Kang-Jey Ho; Hui-Chien Kuo; Henri van der Heyde; Craig Elmets; Pi-Ling Chang
Journal:  Int J Cancer       Date:  2011-10-20       Impact factor: 7.396

Review 4.  Oncoprotein metastasis and its suppression revisited.

Authors:  Razvan T Radulescu
Journal:  J Exp Clin Cancer Res       Date:  2010-04-09

Review 5.  OPN -Revisited.

Authors:  Vijayanirmala Subraman; Muthukumar Thiyagarajan; N Malathi; Sharada T Rajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

6.  Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study.

Authors:  Vijaya Nirmala Subramani; Malathi Narasimhan; Muthukumar Thiyagarajan; Balu David Munuswamy; Logeswari Jayamani
Journal:  J Clin Diagn Res       Date:  2015-11-01

7.  Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Authors:  Pi-Ling Chang; Yu-Hua Hsieh; Chao-Cheng Wang; M Margaret Juliana; Yuko Tsuruta; Laura Timares; Craig Elmets; Kang-Jey Ho
Journal:  J Dermatol Sci       Date:  2014-05-21       Impact factor: 4.563

8.  Osteopontin expression in normal skin and non-melanoma skin tumors.

Authors:  Pi-Ling Chang; Louie Harkins; Yu-Hua Hsieh; Patricia Hicks; Kraisorn Sappayatosok; Somchai Yodsanga; Somporn Swasdison; Ann F Chambers; Craig A Elmets; Kang-Jey Ho
Journal:  J Histochem Cytochem       Date:  2007-10-15       Impact factor: 2.479

Review 9.  The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.

Authors:  F C Campbell; Haibo Xu; M El-Tanani; P Crowe; V Bingham
Journal:  Biochem Pharmacol       Date:  2009-09-06       Impact factor: 5.858

10.  Osteopontin and oral carcinogenesis.

Authors:  Shailendra Kapoor
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.